DE | Accessible presentation
Translations are powered by AI

How Munich biotech startups are fighting cancer

Munich is one of Germany's leading biotech hubs. Research is being conducted here on a wide variety of drugs and therapies, including cancer treatments. We'll introduce you to five startups in more detail.

February 21, 2023

Tubules
Tubules develops antibody-drug conjugates (ADCs) designed to attack tumors. These compounds enable the targeted delivery of substances to the tissue affected by a disease. In the case of cancer, this enables, for example, the targeted delivery of chemotherapeutic agents to cancer cells without releasing large amounts of toxic substances into healthy tissue. Founded in 2019 as a spin-off of the Leibniz Research Institute Berlin (FMP) and Ludwig Maximilian University (LMU), the company focuses on stabilizing these ADCs to expand their potential applications. In May 2022, Tubulis raised an additional €60 million in its Series B round, bringing its total funding to approximately €72 million. (Image: Carolin Bleese)
read more ↓